AAP
PRME icon

Arax Advisory Partners’s Prime Medicine PRME Stock Holding History

Arax Advisory Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.55K Buy
961
+731
+318% +$2.43K ﹤0.01% 4677
2026
Q1 		$800 Buy
+230
New +$875 ﹤0.01% 3342
2025
Q4 		– Sell
-5,406
Closed -$29.9K – 4436
2025
Q3 		$29.9K Buy
+5,406
New +$22K ﹤0.01% 2084
2024
Q4 		– Sell
-139
Closed -$538 – 2676
2024
Q3 		$538 Hold
139
– – ﹤0.01% 2390
2024
Q2 		$715 Buy
+139
New +$843 ﹤0.01% 2263

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Arax Advisory Partners's PRME Position: Q2 2026 in Review

Arax Advisory Partners increased its Prime Medicine (PRME) stake by 318% in Q2 2026, buying an estimated $2.43K and bringing the position to 961 shares worth $3.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4677.

Arax Advisory Partners first reported a position in PRME in Q2 2024 and has held it in 5 quarters since. The position peaked at $29.9K in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Arax Advisory Partners held 961 shares of Prime Medicine worth $3.55K as of Q2 2026.
  • Arax Advisory Partners bought 731 Prime Medicine shares in Q2 2026, an estimated $2.43K.
  • Prime Medicine made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4677 holding.
  • Arax Advisory Partners first reported a position in Prime Medicine in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Prime Medicine position peaked at $29.9K in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.